Bristol-Myers Squibb announced a multi-year expansion of its biologics manufacturing agreement with Lonza.
Bristol-Myers Squibb (BMS) announced on Oct. 30, 2014 that it would expand its existing biologics manufacturing agreement to include the production of commercial quantities of a second BMS biologic medicine at Lonza’s mammalian manufacturing facility in Portsmouth, New Hampshire.
BMS and Lonza have collaborated since 2003 to produce commercial supplies of a biologics medicine. Lonza also produces clinical supplies of an investigational biologics medicine for BMS.
Source: Bristol-Myers Squibb
Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates
Published: January 13th 2025 | Updated: January 13th 2025The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.